The CDP scheme aims to increase the number of new treatments for cancer patients by taking more novel oncology agents into clinical development. CDP brings promising anti-cancer agents, which companies are otherwise unable to develop, into clinical trials.
CDP offers companies an alternative path for clinical development. It provides a unique opportunity to work with us, and enables companies to realise the full potential of their oncology pipelines for the benefit of people with cancer. We are looking to partner with leading pharmaceutical and biotechnology companies who require resource, capabilities or expertise to develop new agents for the treatment of cancer.
Since its formation, CDP has seen 18 treatments enter the programme, with 11 currently in active development and 3 completed.
For more information about the CDP initiative, contact the team at: